Company intelligence / Profile preview

Exadel

Walnut Creek, California, United Statesexadel.com ↗

Ownership: Private
Development stage: Other

Overview

Exadel is a global software consulting and development company specializing in digital transformation across multiple industries, including healthcare, pharma, and biotech. It builds custom technology solutions such as AI-powered analytics platforms for cancer research, e-commerce supply chain systems for healthcare procurement, telehealth applications, and tools supporting global clinical trials. While Exadel does not directly develop therapeutics or diagnostics as products of its own, it enables innovation in life sciences through advanced IT services[1][2][3][4][5][6].

Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Not specifically listed; collaborates with major cloud providers like Microsoft Azure on client projects[4], and works with various bioinformatics firms and healthcare organizations as clients.

Beyond the preview

Go deeper on Exadel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exadel.

Explore the full profile